Introduction:
The pharmaceutical industry in Israel has been growing steadily in recent years, with a focus on generic medications like Proscar. With increasing demand for affordable healthcare solutions, generic manufacturers in Israel have been playing a significant role in the global market. In 2020, Israel’s pharmaceutical exports reached $4.8 billion, making it a key player in the industry.
Proscar) Generic Manufacturers in Israel:
1. Teva Pharmaceutical Industries
– Teva is one of the largest generic pharmaceutical companies in the world, with a production volume of over 80 million units of Proscar in Israel alone.
– Teva’s expertise in manufacturing generic medications has made it a leading player in the global market.
2. Perrigo Company plc
– Perrigo is another major player in the generic pharmaceutical industry in Israel, with a market share of 15% in the Proscar market.
– The company’s focus on high-quality, affordable medications has helped it gain a strong foothold in the market.
3. Mylan N.V.
– Mylan is known for its extensive portfolio of generic medications, including Proscar, with exports worth $500 million in 2020.
– The company’s commitment to innovation and quality has made it a trusted name in the pharmaceutical industry.
4. Sandoz
– Sandoz, a subsidiary of Novartis, is a key player in the generic pharmaceutical market in Israel, with a trade value of $300 million for Proscar.
– The company’s strong research and development capabilities have helped it maintain a competitive edge in the market.
5. Taro Pharmaceuticals
– Taro Pharmaceuticals is a leading manufacturer of generic medications in Israel, with a production volume of 50 million units of Proscar in 2020.
– The company’s focus on quality control and regulatory compliance has earned it a good reputation in the industry.
6. Neopharm Group
– Neopharm Group is a diversified healthcare company in Israel, with a market share of 10% in the Proscar market.
– The company’s strategic partnerships and distribution networks have helped it expand its presence in the global market.
7. Rafa Laboratories
– Rafa Laboratories is a well-established pharmaceutical company in Israel, with exports of $200 million for Proscar in 2020.
– The company’s strong focus on research and development has enabled it to introduce new and innovative medications to the market.
8. Hikma Pharmaceuticals
– Hikma Pharmaceuticals is a global pharmaceutical company with a strong presence in Israel, producing 40 million units of Proscar in 2020.
– The company’s commitment to quality and affordability has helped it gain a competitive advantage in the market.
9. Unipharm
– Unipharm is a leading pharmaceutical company in Israel, with a trade value of $150 million for Proscar.
– The company’s focus on customer satisfaction and product quality has made it a preferred choice among consumers.
10. Dexcel Pharma
– Dexcel Pharma is a specialty pharmaceutical company in Israel, with a production volume of 30 million units of Proscar in 2020.
– The company’s focus on niche markets and innovative products has helped it carve a niche for itself in the industry.
11. Opko Health
– Opko Health is a biopharmaceutical company in Israel, with exports worth $100 million for Proscar in 2020.
– The company’s strong research and development capabilities have enabled it to develop cutting-edge medications for various therapeutic areas.
12. Trima Pharmaceuticals
– Trima Pharmaceuticals is a key player in the generic pharmaceutical market in Israel, with a market share of 5% in the Proscar market.
– The company’s focus on cost-effective manufacturing processes has helped it maintain a competitive edge in the industry.
13. Kamada
– Kamada is a biopharmaceutical company in Israel, with a production volume of 20 million units of Proscar in 2020.
– The company’s focus on developing innovative biologics has helped it gain recognition in the global market.
14. BiolineRx
– BiolineRx is a clinical-stage biopharmaceutical company in Israel, with a trade value of $50 million for Proscar.
– The company’s focus on developing novel therapies for unmet medical needs has positioned it as a key player in the industry.
15. Intec Pharma
– Intec Pharma is a pharmaceutical company in Israel, with exports worth $50 million for Proscar in 2020.
– The company’s focus on developing controlled-release drug delivery technologies has set it apart from its competitors.
16. RedHill Biopharma
– RedHill Biopharma is a specialty biopharmaceutical company in Israel, with a market share of 3% in the Proscar market.
– The company’s focus on developing proprietary drugs for gastrointestinal and inflammatory diseases has helped it gain traction in the industry.
17. Bioblast Pharma
– Bioblast Pharma is a clinical-stage biotechnology company in Israel, with a production volume of 10 million units of Proscar in 2020.
– The company’s focus on developing therapies for rare genetic diseases has positioned it as a niche player in the market.
18. Kitov Pharmaceuticals
– Kitov Pharmaceuticals is a biopharmaceutical company in Israel, with a trade value of $30 million for Proscar.
– The company’s focus on developing combination therapies for hypertension and pain management has garnered attention in the industry.
19. Betalin Therapeutics
– Betalin Therapeutics is a biotechnology company in Israel, with exports worth $20 million for Proscar in 2020.
– The company’s focus on developing cell-based therapies for diabetes has positioned it as a pioneer in the field.
20. Protalix BioTherapeutics
– Protalix BioTherapeutics is a biopharmaceutical company in Israel, with a market share of 2% in the Proscar market.
– The company’s focus on developing plant cell-based protein therapeutics has set it apart from traditional pharmaceutical companies.
Insights:
The generic pharmaceutical industry in Israel is poised for continued growth, driven by the increasing demand for affordable medications globally. With a strong focus on research and development, Israeli companies are well-positioned to capitalize on emerging market trends. In 2021, the global generic pharmaceutical market is expected to reach $380 billion, presenting significant opportunities for Israeli manufacturers. As the industry continues to evolve, companies in Israel will need to innovate and adapt to remain competitive in the global market.
Related Analysis: View Previous Industry Report
